120277-68-1

Basic information

• Product Name: Pyridine, 3-(chloromethyl)-2-methyl- (9CI)
• Synonyms: Pyridine, 3-(chloromethyl)-2-methyl- (9CI);3-(ChloroMethyl)-2-Methylpyridine;2-Methyl-3-(chloromethyl)pyridine
• CAS NO: 120277-68-1
• Molecular Formula: C₇H₈ClN
• Molecular Weight: 141.59812
• Product Categories: PYRIDINE;Aromatics, Heterocycles, Intermediates, Metabolites & Impurities
• Mol File: 120277-68-1.mol

Chemical Properties

• Boiling Point: 219.521ºC at 760 mmHg
• Flash Point: 107.422ºC
• Appearance: /
• Density: 1.118g/cm3
• Vapor Pressure: 0.176mmHg at 25°C
• Refractive Index: 1.527
• Storage Temp.: 2-8°C
• Solubility: Dichloromethane, Ethyl Acetate, Methanol
• CAS DataBase Reference: Pyridine, 3-(chloromethyl)-2-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 3-(chloromethyl)-2-methyl- (9CI)(120277-68-1)
• EPA Substance Registry System: Pyridine, 3-(chloromethyl)-2-methyl- (9CI)(120277-68-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 120277-68-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Pyridine, 3-(chloromethyl)-2-methyl(9CI) is used as a key intermediate in the synthesis of oxytocin antagonists and inhibitors of aggrecanase and MMP-13. These compounds play a crucial role in the development of drugs targeting various physiological processes and diseases.
As an intermediate in the preparation of Oxytocin Antagonists:
Pyridine, 3-(chloromethyl)-2-methyl(9CI) is utilized for the synthesis of oxytocin antagonists, which are important in the development of drugs for the treatment of various conditions, such as postpartum hemorrhage and preterm labor. These antagonists help regulate the release of oxytocin, a hormone that plays a significant role in childbirth and social bonding.
As an intermediate in the preparation of Inhibitors of Aggrecanase and MMP-13:
Pyridine, 3-(chloromethyl)-2-methyl(9CI) is also used in the synthesis of inhibitors targeting aggrecanase and MMP-13 enzymes. These inhibitors are essential in the development of therapeutic agents for the treatment of osteoarthritis and other degenerative joint diseases. By inhibiting the activity of these enzymes, the breakdown of cartilage and joint damage can be reduced, thus alleviating the symptoms and progression of the disease.

InChI:InChI=1/C7H8ClN/c1-6-7(5-8)3-2-4-9-6/h2-4H,5H2,1H3

Upstream product

• 65719-09-7 methyl 2-methylnicotinate 
• 60032-57-7 2-methylnicotinaldehyde 
• 1721-26-2 ethyl 2-methyl nicotinate 
• 56826-61-0 (2-methylpyridin-3-yl)methanol 

Downstream Products

• 1421928-59-7 ethyl 2-(4-((2-methylpyridin-3-yl)methoxy)phenyl)acetate 
• 1421928-19-9 C₃₀H₃₁N₃O 
• 1421928-23-5 C₃₁H₃₂N₂O₂ 
• 1421928-47-3 C₃₀H₂₉ClN₂O₂ 
• 1421928-60-0 2-(4-((2-methylpyridin-3-yl)methoxy)phenyl)acetic acid hydrochloride 
• 1421928-11-1 C₂₉H₂₇ClN₂O₂ 
• 101166-73-8 (2-methylpyridin-3-yl)acetonitrile 
• 1421928-16-6 C₂₇H₃₁ClN₂O₂ 
• 162045-26-3 1-(1-4-(1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxyl-2-methoxybenzoyl)piperidin-4-yl)-1,4-dihydrobenz(d)(1,3)oxazin-2-one 

Relevant articles and documents

COMPOUNDS AND METHODS

The present invention relates to novel retinoid-related orphan receptor gamma (RORy) modulators and their use in the treatment of diseases mediated by RORy.

(3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. (Formula)

COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE

Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and haloge

4-(PYRIDIN-3-YL)-2-(PYRIDIN-2-YL)-1,2-DIHYDRO-3H-PYRAZOL-3-ONE DERIVATIVES AS SPECIFIC HIF-PROLYL-4-HYDROXYLASE INHIBITORS FOR TREATING CARDIOVASCULAR AND HAEMATOLOGICAL DISEASES

The object of the invention is to provide new compounds which can be used for the treatment of diseases, in particular cardiovascular and haematological diseases. The present invention describes compounds which act as specific HIF-prolyl-4-hydroxylase inhibitors and which, because of this specific in vivo action mechanism, induce HIF target genes, such as erythropoietin, and the thus produced biological processes, such as erythropoiesis, after parenteral or oral administration. The present invention relates to compounds having the general formula (I), in which A stands for CH or N, R1 stands for a substituent selected from the group formed by (C1-C6)-alkyl, trifluoromethyl, halogen, cyano, nitro, hydroxy, (C1-C6)-alkoxy, amino, (C1-C6)-alkoxycarbonyl, hydroxycarbonyl and C(=O)-NH-R4; R2 stands for a substituent selected from the group formed by halogen, cyano, nitro, (C1-C6)-alkyl, trifluoromethyl, hydroxy, (C1-C6)-alkoxy, trifluoromethoxy, amino, hydroxycarbonyl and C(=O)-NH-R8; m equals 0, 1 or 2; n equals 0, 1, 2 or 3, it being possible for these meanings to be the same or different when R1 or R2 occurs multiple times; and R3 stands for hydrogen, (C1-C6)-alkyl or (C3-C7)-cycloalkyl. The invention also relates to the salts, solvates, and salt solvates of these compounds.

Novel tricyclic pyridyl carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists

This invention provides novel substituted tricyclic pyridyl carboxamides which act as oxytocin receptor competitive antagonists, as well as methods of their manufacture, pharmaceutical compositions and methods of their use in treatment, inhibition, suppression or prevention of preterm labor, dysmenorrhea, endometritis, suppression of labor at term prior to caesarean delivery, and to facilitate antinatal transport to a medical facility. These compounds are also useful in enhancing fertility rates, enhancing survival rates and synchronizing estrus in farm animals; and may be useful in the prevention and treatment of disfunctions of the oxytocin system in the central nervous system including obsessive compulsive disorder (OCD) and neuropsychiatric disorders.

Development of orally active oxytocin antagonists: Studies on 1-(1-{4- [1-(2-methyl-1-oxidopyridin-3-ylmethyl)piperidin-4-yloxy].2methoxybenzoyl}- 4-yl)-1,4-dihydrobenz[d][1,3]oxazin-2-one (L-372,662) and related pyridines

The previously reported oxytocin antagonist L-371,257 (2) has been modified at its acetylpiperidine terminus to incorporate various pyridine N- oxide groups. This modification has led to the identification of compounds with improved pharmacokinetics and excellent oral bioavailability. The pyridine N-oxide series is exemplified by L-372,662 (30), which possessed good potency in vitro (Ki = 4.1 nM, cloned human oxytocin receptor) and in vivo (intravenous AD50 = 0.71 mg/kg in the rat), excellent oral bioavailability (90% in the rat, 96% in the dog), good aqueous solubility (>8.5 mg/mL at pH 5.2) which should facilitate formulation for iv administration, and excellent selectivity against the human arginine vasopressin receptors. Incorporation of a 5-fluoro substituent on the central benzoyl ring of this class of oxytocin antagonists enhanced in vitro and in vivo potency but was detrimental to the pharmacokinetic profiles of these compounds. Although lipophilic substitution around the pyridine ring of compound 30 gave higher affinity in vitro, such substituents were a metabolic liability and caused shortfalls in vivo. Two approaches to prevent this metabolism, addition of a cyclic constraint and incorporation of trifluoromethyl groups, were examined. The former approach was ineffective because of metabolic hydroxylation on the constrained ring system, whereas the latter showed improvement in plasma pharmacokinetics in some cases.

TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS

This invention relates to certain novel benzoxazinone compounds and derivatives thereof, their synthesis, and their use as oxytocin receptor antagonists. One application of these compounds is in the treatment of preterm labor. The ability of the compounds to relax uterine contractions in mammals also makes them useful for treating dysmenorrhea and stopping labor prior to cesarean delivery. A typical compound is as follows: STR1

Inhibitors of farnesyl-protein transferase

The present invention is directed to compounds which inhibit farnesyl-protein transferase (FTase) and the farnesylation of the oncogene protein Ras. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for inhibiting farnesyl-protein transferase and treatment of cancer.